As we know GRK2 is upregulated in various kidney diseases, GRK2 inhibition might be an innovative therapeutic strategy to treat renal diseases, such as SLE‐related kidney injury, DN, age‐related kidney injury, hypertension‐related kidney injury, and CRS. The gene discussed is GRK2; the disease is systemic lupus erythematosus.